{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T14:44:41Z","timestamp":1782830681007,"version":"3.54.5"},"reference-count":129,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T00:00:00Z","timestamp":1782172800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T00:00:00Z","timestamp":1782172800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100023674","name":"Deanship of Scientific Research, King Khalid University","doi-asserted-by":"publisher","award":["RGP1\/167\/46"],"award-info":[{"award-number":["RGP1\/167\/46"]}],"id":[{"id":"10.13039\/501100023674","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"DOI":"10.1007\/s12032-026-03307-5","type":"journal-article","created":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T12:32:29Z","timestamp":1782217949000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Harnessing nanoparticles to unlock the therapeutic potential of triptolide in cancer treatment"],"prefix":"10.1007","volume":"43","author":[{"given":"Sambhavi","family":"Swarn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanvi","family":"Desai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonam M","family":"Gandhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vipin","family":"Saini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shadma","family":"Wahab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4085-8936","authenticated-orcid":false,"given":"Devesh U","family":"Kapoor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,23]]},"reference":[{"key":"3307_CR1","doi-asserted-by":"crossref","unstructured":"Abdallah AE, Elkady H, Elwan A, Rashed M, Hammad A, Elkady MA, Elsakka EGE, Alesawy MS. (2025) New vatalanib analogs: Design, synthesis, in silico study and biological evaluation for anticancer activity. J Mol Struct 1322.","DOI":"10.1016\/j.molstruc.2024.140595"},{"key":"3307_CR2","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1002\/biof.1944","volume":"49","author":"AH AbdulHussein","year":"2023","unstructured":"AbdulHussein AH, Al-Taee MM, Radih ZA, Aljuboory DS, Mohammed ZQ, Hashesh TS, Riadi Y, Hadrawi SK, Najafi M. Mechanisms of cancer cell death induction by triptolide. BioFactors. 2023;49:718\u201335.","journal-title":"BioFactors"},{"key":"3307_CR3","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1007\/s00280-014-2498-5","volume":"74","author":"HK Ahn","year":"2014","unstructured":"Ahn HK, Jung M, Sym SJ, Shin DB, Kang SM, Kyung SY, Park JW, Jeong SH, Cho EK. A phase II trial of Cremorphor EL-free paclitaxel (Genexol-PM) and gemcitabine in patients with advanced non-small cell lung cancer. Cancer Chemother Pharmacol. 2014;74:277\u201382.","journal-title":"Cancer Chemother Pharmacol"},{"key":"3307_CR4","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/j.sajb.2025.03.004","volume":"180","author":"MS Al Hasan","year":"2025","unstructured":"Al Hasan MS, Bhuia MS, Chowdhury R, Shadin M, Mia E, Yana NT, Rakib IH, Ansari SA, Ansari IA, Coutinho HDM, Islam MT. Anticancer activity of Jasminum sambac and its bioactive phytochemicals against the PI3K-AKT-mTOR pathway: A literature-based in silico study. South Afr J Bot. 2025;180:431\u201343.","journal-title":"South Afr J Bot"},{"key":"3307_CR5","doi-asserted-by":"publisher","first-page":"e202402479","DOI":"10.1002\/cbdv.202402479","volume":"22","author":"AAA Aljabali","year":"2025","unstructured":"Aljabali AAA, Obeid MA, Bashatwah RM, Qnais E, Gammoh O, Alqudah A, Mishra V, Mishra Y, Khan MA, Parvez S, El-Tanani M, Hatahet T. Phytochemicals in Cancer Therapy: A Structured Review of Mechanisms, Challenges, and Progress in Personalized Treatment. Chem Biodivers. 2025;22:e202402479.","journal-title":"Chem Biodivers"},{"key":"3307_CR6","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.addr.2012.09.037","volume":"65","author":"TM Allen","year":"2013","unstructured":"Allen TM, Cullis PR. Liposomal drug delivery systems: from concept to clinical applications. Adv Drug Deliv Rev. 2013;65:36\u201348.","journal-title":"Adv Drug Deliv Rev"},{"key":"3307_CR7","doi-asserted-by":"publisher","first-page":"821","DOI":"10.3390\/cancers17050821","volume":"17","author":"S Bandara","year":"2025","unstructured":"Bandara S, Raveendran S. Current landscape and future directions in cancer immunotherapy: therapies, trials, and challenges. Cancers. 2025a;17:821.","journal-title":"Cancers"},{"key":"3307_CR8","doi-asserted-by":"crossref","unstructured":"Bandara S, Raveendran S. (2025b) Current Landscape and Future Directions in Cancer Immunotherapy: Therapies, Trials, and Challenges. Cancers (Basel) 17.","DOI":"10.3390\/cancers17050821"},{"key":"3307_CR9","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1186\/s12935-024-03336-y","volume":"24","author":"S Bao","year":"2024","unstructured":"Bao S, Yi M, Xiang B, Chen P. Antitumor mechanisms and future clinical applications of the natural product triptolide. Cancer Cell Int. 2024a;24:150.","journal-title":"Cancer Cell Int"},{"key":"3307_CR10","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1186\/s12935-024-03336-y","volume":"24","author":"S Bao","year":"2024","unstructured":"Bao S, Yi M, Xiang B, Chen P. Antitumor mechanisms and future clinical applications of the natural product triptolide. Cancer Cell Int. 2024b;24:150.","journal-title":"Cancer Cell Int"},{"key":"3307_CR11","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.jconrel.2012.03.020","volume":"160","author":"Y Barenholz","year":"2012","unstructured":"Barenholz Y. Doxil(R)--the first FDA-approved nano-drug: lessons learned. J Control Release. 2012;160:117\u201334.","journal-title":"J Control Release"},{"key":"3307_CR12","doi-asserted-by":"publisher","first-page":"4218","DOI":"10.1039\/C6CS00636A","volume":"46","author":"S Behzadi","year":"2017","unstructured":"Behzadi S, Serpooshan V, Tao W, Hamaly MA, Alkawareek MY, Dreaden EC, Brown D, Alkilany AM, Farokhzad OC, Mahmoudi M. Cellular uptake of nanoparticles: journey inside the cell. Chem Soc Rev. 2017;46:4218\u201344.","journal-title":"Chem Soc Rev"},{"key":"3307_CR13","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1038\/nbt.3330","volume":"33","author":"E Blanco","year":"2015","unstructured":"Blanco E, Shen H, Ferrari M. Principles of nanoparticle design for overcoming biological barriers to drug delivery. Nat Biotechnol. 2015;33:941\u201351.","journal-title":"Nat Biotechnol"},{"key":"3307_CR14","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1007\/s11605-009-1065-6","volume":"14","author":"D Borja-Cacho","year":"2010","unstructured":"Borja-Cacho D, Yokoyama Y, Chugh RK, Mujumdar NR, Dudeja V, Clawson KA, Dawra RK, Saluja AK, Vickers SM. TRAIL and triptolide: an effective combination that induces apoptosis in pancreatic cancer cells. J Gastrointest Surg. 2010;14:252\u201360.","journal-title":"J Gastrointest Surg"},{"key":"3307_CR15","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1186\/s12943-023-01865-0","volume":"22","author":"M Chehelgerdi","year":"2023","unstructured":"Chehelgerdi M, Chehelgerdi M, Allela OQB, Pecho RDC, Jayasankar N, Rao DP, Thamaraikani T, Vasanthan M, Viktor P, Lakshmaiya N, Saadh MJ, Amajd A, Abo-Zaid MA, Castillo-Acobo RY, Ismail AH, Amin AH, Akhavan-Sigari R. Progressing nanotechnology to improve targeted cancer treatment: overcoming hurdles in its clinical implementation. Mol Cancer. 2023;22:169.","journal-title":"Mol Cancer"},{"key":"3307_CR16","doi-asserted-by":"publisher","first-page":"6991","DOI":"10.7150\/thno.101606","volume":"14","author":"D Chen","year":"2024","unstructured":"Chen D, Xu J, Lv S, Jin X, Chen Y, Cai H, Wang Q, Xuan X, Wang G, Fei W, Chen J. Enzyme-activatable kidney-targeted dendrimer-drug conjugate for efficient childhood nephrotic syndrome therapy. Theranostics. 2024;14:6991\u20137006.","journal-title":"Theranostics"},{"key":"3307_CR17","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1016\/j.apsb.2015.09.006","volume":"5","author":"G Chen","year":"2015","unstructured":"Chen G, Hao B, Ju D, Liu M, Zhao H, Du Z, Xia J. Pharmacokinetic and pharmacodynamic study of triptolide-loaded liposome hydrogel patch under microneedles on rats with collagen-induced arthritis. Acta Pharm Sin B. 2015;5:569\u201376.","journal-title":"Acta Pharm Sin B"},{"key":"3307_CR18","doi-asserted-by":"publisher","first-page":"123623","DOI":"10.1016\/j.ijpharm.2023.123623","volume":"648","author":"H Chen","year":"2023","unstructured":"Chen H, Wang X, Liu M, Yang J, Kuang Y, Wei R, Tai Z, Zhu Q, Chen Z, Chen J, Wu X. Synergism and attenuation of triptolide through prodrug engineering combined with liposomal scaffold strategy to enhance inhibition in pancreatic cancer. Int J Pharm. 2023;648:123623.","journal-title":"Int J Pharm"},{"key":"3307_CR19","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.ejpb.2021.04.025","volume":"165","author":"K-J Chen","year":"2021","unstructured":"Chen K-J, Plaunt AJ, Leifer FG, Kang JY, Cipolla D. Recent advances in prodrug-based nanoparticle therapeutics. Eur J Pharm Biopharm. 2021;165:219\u201343.","journal-title":"Eur J Pharm Biopharm"},{"key":"3307_CR20","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1186\/s13020-021-00525-z","volume":"16","author":"Y Cheng","year":"2021","unstructured":"Cheng Y, Zhao Y, Zheng Y. Therapeutic potential of triptolide in autoimmune diseases and strategies to reduce its toxicity. Chin Med. 2021;16:114.","journal-title":"Chin Med"},{"key":"3307_CR21","doi-asserted-by":"publisher","first-page":"110651","DOI":"10.1016\/j.cbi.2023.110651","volume":"382","author":"D Cui","year":"2023","unstructured":"Cui D, Xu D, Yue S, Yan C, Liu W, Fu R, Ma W, Tang Y. Recent advances in the pharmacological applications and liver toxicity of triptolide. Chemico-Biol Interact. 2023;382:110651.","journal-title":"Chemico-Biol Interact"},{"key":"3307_CR22","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.cpt.2024.11.002","volume":"3","author":"VC Deivayanai","year":"2025","unstructured":"Deivayanai VC, Thamarai P, Karishma S, Saravanan A, Yaashikaa PR, Vickram AS, Hemavathy RV, Kumar RR, Rishikesavan S, Shruthi S. Advances in nanoparticle-mediated cancer therapeutics: Current research and future perspectives. Cancer Pathog Ther. 2025;3:293\u2013308.","journal-title":"Cancer Pathog Ther"},{"key":"3307_CR23","doi-asserted-by":"publisher","first-page":"189241","DOI":"10.1016\/j.bbcan.2024.189241","volume":"1880","author":"R Deng","year":"2025","unstructured":"Deng R, Zong GF, Wang X, Yue BJ, Cheng P, Tao RZ, Li X, Wei ZH, Lu Y. Promises of natural products as clinical applications for cancer. Biochim Biophys Acta Rev Cancer. 2025;1880:189241.","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"3307_CR24","doi-asserted-by":"publisher","first-page":"11739","DOI":"10.1039\/C7NR03016A","volume":"9","author":"B Ding","year":"2017","unstructured":"Ding B, Wahid MA, Wang Z, Xie C, Thakkar A, Prabhu S, Wang J. Triptolide and celastrol loaded silk fibroin nanoparticles show synergistic effect against human pancreatic cancer cells. Nanoscale. 2017;9:11739\u201353.","journal-title":"Nanoscale"},{"key":"3307_CR25","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1016\/j.apsb.2021.08.020","volume":"12","author":"S Dong","year":"2022","unstructured":"Dong S, Guo X, Han F, He Z, Wang Y. Emerging role of natural products in cancer immunotherapy. Acta Pharm Sinica B. 2022;12:1163\u201385.","journal-title":"Acta Pharm Sinica B"},{"key":"3307_CR26","doi-asserted-by":"crossref","unstructured":"Etheridge ML, Campbell SA, Erdman AG, Haynes CL, Wolf SM. McCullough JJNn, biology, medicine (2013) The big picture on nanomedicine: the state of investigational and approved nanomedicine products. 9: 1\u201314.","DOI":"10.1016\/j.nano.2012.05.013"},{"key":"3307_CR27","doi-asserted-by":"crossref","unstructured":"Faria M, Bj\u00f6rnmalm M, Thurecht KJ, Kent SJ, Parton RG, Kavallaris M, Johnston AP, Gooding JJ, Corrie SR, Boyd BJJN. (2018) Minimum information reporting in bio\u2013nano experimental literature. 13: 777\u201385.","DOI":"10.1038\/s41565-018-0246-4"},{"key":"3307_CR28","doi-asserted-by":"publisher","first-page":"e24335","DOI":"10.1016\/j.heliyon.2024.e24335","volume":"10","author":"K Feng","year":"2024","unstructured":"Feng K, Li X, Bai Y, Zhang D, Tian L. Mechanisms of cancer cell death induction by triptolide: A comprehensive overview. Heliyon. 2024;10:e24335.","journal-title":"Heliyon"},{"key":"3307_CR29","doi-asserted-by":"crossref","unstructured":"Fu M, Han X, Chen B, Guo L, Zhong L, Hu P, Pan Y, Qiu M, Cao P, Chen J. (2022) Cancer treatment: from traditional Chinese herbal medicine to the liposome delivery system. Acta Materia Medica 1.","DOI":"10.15212\/AMM-2022-0035"},{"key":"3307_CR30","doi-asserted-by":"crossref","unstructured":"Gaikwad SS, Morade YY, Kothule AM, Kshirsagar SJ, Laddha UD, Salunkhe KS. (2023) Overview of phytosomes in treating cancer: Advancement, challenges, and future outlook. Heliyon 9.","DOI":"10.1016\/j.heliyon.2023.e16561"},{"key":"3307_CR31","doi-asserted-by":"publisher","first-page":"905576","DOI":"10.3389\/fphar.2022.905576","volume":"13","author":"W Gang","year":"2022","unstructured":"Gang W, Hao H, Yong H, Ruibing F, Chaowen L, Yizheng H, Chao L, Haitao Z. Therapeutic Potential of Triptolide in Treating Bone-Related Disorders. Front Pharmacol. 2022;13:905576.","journal-title":"Front Pharmacol"},{"key":"3307_CR32","doi-asserted-by":"publisher","first-page":"7199","DOI":"10.7150\/thno.57745","volume":"11","author":"J Gao","year":"2021","unstructured":"Gao J, Zhang Y, Liu X, Wu X, Huang L, Gao W. Triptolide: pharmacological spectrum, biosynthesis, chemical synthesis and derivatives. Theranostics. 2021a;11:7199\u2013221.","journal-title":"Theranostics"},{"key":"3307_CR33","doi-asserted-by":"publisher","first-page":"7199","DOI":"10.7150\/thno.57745","volume":"11","author":"J Gao","year":"2021","unstructured":"Gao J, Zhang Y, Liu X, Wu X, Huang L, Gao W. Triptolide: pharmacological spectrum, biosynthesis, chemical synthesis and derivatives. Theranostics. 2021b;11:7199.","journal-title":"Theranostics"},{"key":"3307_CR34","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1007\/s12032-025-02754-w","volume":"42","author":"SSS Garemilla","year":"2025","unstructured":"Garemilla SSS, Gampa SC, Garimella S. Role of the tumor microenvironment in cancer therapy: unveiling new targets to overcome drug resistance. Med Oncol. 2025;42:202.","journal-title":"Med Oncol"},{"key":"3307_CR35","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.3390\/genes15101287","volume":"15","author":"D Gorrie","year":"2024","unstructured":"Gorrie D, Bravo M, Fan L. The Yin and Yang of the Natural Product Triptolide and Its Interactions with XPB, an Essential Protein for Gene Expression and DNA Repair. Genes. 2024;15:1287.","journal-title":"Genes"},{"key":"3307_CR36","doi-asserted-by":"publisher","first-page":"eadv6990","DOI":"10.1126\/sciadv.adv6990","volume":"11","author":"Y Gu","year":"2025","unstructured":"Gu Y, Li A, Zeng Y, He M, Qi F, Liu R, Cai H, Li D, Tang X, Fu Z. Engineering hybrid nanoparticles for targeted codelivery of triptolide and CYP3A4-siRNA against pulmonary metastatic melanoma. Sci Adv. 2025a;11:eadv6990.","journal-title":"Sci Adv"},{"key":"3307_CR37","doi-asserted-by":"publisher","first-page":"eadv6990","DOI":"10.1126\/sciadv.adv6990","volume":"11","author":"Y Gu","year":"2025","unstructured":"Gu Y, Li A, Zeng Y, He M, Qi F, Liu R, Cai H, Li D, Tang X, Fu Z, Wu X, Liu J. Engineering hybrid nanoparticles for targeted codelivery of triptolide and CYP3A4-siRNA against pulmonary metastatic melanoma. Sci Adv. 2025b;11:eadv6990.","journal-title":"Sci Adv"},{"key":"3307_CR38","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/s12951-018-0389-3","volume":"16","author":"Y Gu","year":"2018","unstructured":"Gu Y, Yang M, Tang X, Wang T, Yang D, Zhai G, Liu J. Lipid nanoparticles loading triptolide for transdermal delivery: mechanisms of penetration enhancement and transport properties. J Nanobiotechnol. 2018;16:68.","journal-title":"J Nanobiotechnol"},{"key":"3307_CR39","doi-asserted-by":"crossref","unstructured":"Habeeb M, Deepthi KL, Vengateswaran HT, Arsey S, You HW, Aher KBJB. (2025) Innovations in metal-based nanomedicines to interfere with the signaling communications of prostate cancer. 15: 123.","DOI":"10.1007\/s12668-024-01723-3"},{"key":"3307_CR40","unstructured":"Habeeb M, Vasanthan M. (2024) Cabozantinib Encapsulated Lipid and Polymeric Nanoparticles: In-depth Exploration of Molecular Interactions, Formulation Strategies, and In vitro Studies on Hepatocellular Carcinoma."},{"key":"3307_CR41","unstructured":"Habeeb M, Vasanthan MJIJND. (2025) Formulation, interaction analysis, and invitro hepatocellular carcinoma studies of Rutin loaded lipid and polymeric nanoparticles. 16."},{"key":"3307_CR42","doi-asserted-by":"crossref","unstructured":"Hasan N, Aftab M, Ullah M, Nguyen PT, Agustina R, Djabir YY, Tockary TA, Uchida S. (2025) Nanoparticle-based drug delivery system for Oral Cancer: Mechanism, challenges, and therapeutic potential. Results in Chemistry 14. 102068,1-11 https:\/\/www.sciencedirect.com\/science\/article\/pii\/S2211715625000517","DOI":"10.1016\/j.rechem.2025.102068"},{"key":"3307_CR43","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1166\/jbn.2021.3041","volume":"17","author":"D He","year":"2021","unstructured":"He D, Xu X, Li L, Chen C, Gong K, Guo Q, Liu F, Wang Y, Duan Y, Li H. Functional Exosome-Mediated Delivery of Triptolide Endowed with Targeting Properties as Chemotherapy Carriers for Ovarian Carcinoma. J Biomed Nanotechnol. 2021a;17:426\u201338.","journal-title":"J Biomed Nanotechnol"},{"key":"3307_CR44","doi-asserted-by":"publisher","first-page":"686356","DOI":"10.3389\/fimmu.2021.686356","volume":"12","author":"H He","year":"2021","unstructured":"He H, Takahashi A, Mukai T, Hori A, Narita M, Tojo A, Yang T, Nagamura-Inoue T. The Immunomodulatory Effect of Triptolide on Mesenchymal Stromal Cells. Front Immunol. 2021b;12:686356.","journal-title":"Front Immunol"},{"key":"3307_CR45","doi-asserted-by":"publisher","first-page":"3178","DOI":"10.1016\/j.cclet.2020.05.034","volume":"31","author":"M He","year":"2020","unstructured":"He M, Yu L, Yang Y, Zou B, Ma W, Yu M, Lu J, Xiong G, Yu Z, Li A. Delivery of triptolide with reduction-sensitive polymer nanoparticles for liver cancer therapy on patient-derived xenografts models. Chin Chem Lett. 2020;31:3178\u201382.","journal-title":"Chin Chem Lett"},{"key":"3307_CR46","doi-asserted-by":"publisher","first-page":"12035","DOI":"10.1002\/anie.201606121","volume":"55","author":"QL He","year":"2016","unstructured":"He QL, Minn I, Wang Q, Xu P, Head SA, Datan E, Yu B, Pomper MG, Liu JO. Targeted Delivery and Sustained Antitumor Activity of Triptolide through Glucose Conjugation. Angew Chem Int Ed Engl. 2016;55:12035\u20139.","journal-title":"Angew Chem Int Ed Engl"},{"key":"3307_CR47","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1016\/j.biopha.2018.05.088","volume":"104","author":"ZY Hou","year":"2018","unstructured":"Hou ZY, Tong XP, Peng YB, Zhang BK, Yan M. Broad targeting of triptolide to resistance and sensitization for cancer therapy. Biomed Pharmacother. 2018;104:771\u201380.","journal-title":"Biomed Pharmacother"},{"key":"3307_CR48","doi-asserted-by":"crossref","unstructured":"Hu Y, Song J, Feng A, Li J, Li M, Shi Y, Sun W, Li L. (2023) Recent Advances in Nanotechnology-Based Targeted Delivery Systems of Active Constituents in Natural Medicines for Cancer Treatment. Molecules 28.","DOI":"10.3390\/molecules28237767"},{"key":"3307_CR49","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.3390\/pharmaceutics17081079","volume":"17","author":"S Jacob","year":"2025","unstructured":"Jacob S, Rao R, Gorain B, Boddu SH, Nair AB. Solid Lipid Nanoparticles and Nanostructured Lipid Carriers for Anticancer Phytochemical Delivery: Advances, Challenges, and Future Prospects. Pharmaceutics. 2025;17:1079.","journal-title":"Pharmaceutics"},{"key":"3307_CR50","doi-asserted-by":"publisher","first-page":"42411","DOI":"10.1021\/acsami.1c10325","volume":"13","author":"L Jiang","year":"2021","unstructured":"Jiang L, Gu Y, Du Y, Tang X, Wu X, Liu J. Engineering Exosomes Endowed with Targeted Delivery of Triptolide for Malignant Melanoma Therapy. ACS Appl Mater Interfaces. 2021;13:42411\u201328.","journal-title":"ACS Appl Mater Interfaces"},{"key":"3307_CR51","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.jss.2009.07.002","volume":"168","author":"SM Johnson","year":"2011","unstructured":"Johnson SM, Wang X, Evers BM. Triptolide inhibits proliferation and migration of colon cancer cells by inhibition of cell cycle regulators and cytokine receptors. J Surg Res. 2011;168:197\u2013205.","journal-title":"J Surg Res"},{"key":"3307_CR52","doi-asserted-by":"publisher","first-page":"114694","DOI":"10.1016\/j.ejmech.2022.114694","volume":"243","author":"D Kang","year":"2022","unstructured":"Kang D, Pan X, Song Y, Liu Y, Wang D, Zhu X, Wang J, Hu L. Discovery of a novel water-soluble, rapid-release triptolide prodrug with improved drug-like properties and high efficacy in human acute myeloid leukemia. Eur J Med Chem. 2022a;243:114694.","journal-title":"Eur J Med Chem"},{"key":"3307_CR53","doi-asserted-by":"crossref","unstructured":"Kang D, Pan X, Song Y, Liu Y, Wang D, Zhu X, Wang J, Hu L. (2022b) Discovery of a novel water-soluble, rapid-release triptolide prodrug with improved drug-like properties and high efficacy in human acute myeloid leukemia. Eur J Med Chem 243.","DOI":"10.1016\/j.ejmech.2022.114694"},{"key":"3307_CR54","first-page":"24010003","volume-title":"AI-driven design and optimization of nanoparticle-based drug delivery systems","author":"DU Kapoor","year":"2024","unstructured":"Kapoor DU, Sharma JB, Gandhi SM, Prajapati BG, Thanawuth K, Limmatvapirat S, Sriamornsak P. AI-driven design and optimization of nanoparticle-based drug delivery systems. Engineering and Health Studies: Science; 2024. pp. 24010003\u201324010003."},{"key":"3307_CR55","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/S0169-409X(00)00124-1","volume":"47","author":"K Kataoka","year":"2001","unstructured":"Kataoka K, Harada A, Nagasaki Y. Block copolymer micelles for drug delivery: design, characterization and biological significance. Adv Drug Deliv Rev. 2001;47:113\u201331.","journal-title":"Adv Drug Deliv Rev"},{"key":"3307_CR56","doi-asserted-by":"crossref","unstructured":"Khan G, Ahmad S, Bisht AS, Sultana A, Hussain MS. Triptolide-induced Pyroptosis: A Promising Strategy for Cancer Therapy. Current Nutrition & Food Science; 2025.","DOI":"10.2174\/0115734013383144250730072151"},{"key":"3307_CR57","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1080\/17425247.2021.1860939","volume":"18","author":"V Kumar","year":"2021","unstructured":"Kumar V, Rahman M, Gahtori P, Al-Abbasi F, Anwar F, Kim HS. Current status and future directions of hepatocellular carcinoma-targeted nanoparticles and nanomedicine. Expert Opin Drug Deliv. 2021;18:673\u201394.","journal-title":"Expert Opin Drug Deliv"},{"key":"3307_CR58","doi-asserted-by":"publisher","first-page":"111057","DOI":"10.1016\/j.biopha.2020.111057","volume":"133","author":"CS Kuo","year":"2021","unstructured":"Kuo CS, Yang CY, Lin CK, Lin GJ, Sytwu HK, Chen YW. Triptolide suppresses oral cancer cell PD-L1 expression in the interferon-\u03b3-modulated microenvironment in vitro, in vivo, and in clinical patients. Biomed Pharmacother. 2021;133:111057.","journal-title":"Biomed Pharmacother"},{"key":"3307_CR59","doi-asserted-by":"publisher","first-page":"46","DOI":"10.3390\/pharmaceutics17010046","volume":"17","author":"Y Lei","year":"2025","unstructured":"Lei Y, Liu J, Bai Y, Zheng C, Wang D. Peptides as versatile regulators in cancer immunotherapy: recent advances, challenges, and future prospects. Pharmaceutics. 2025;17:46.","journal-title":"Pharmaceutics"},{"key":"3307_CR60","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s12951-022-01264-5","volume":"20","author":"L Li","year":"2022","unstructured":"Li L, He D, Guo Q, Zhang Z, Ru D, Wang L, Gong K, Liu F, Duan Y, Li H. Exosome-liposome hybrid nanoparticle codelivery of TP and miR497 conspicuously overcomes chemoresistant ovarian cancer. J Nanobiotechnol. 2022;20:50.","journal-title":"J Nanobiotechnol"},{"key":"3307_CR61","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1038\/s41401-023-01219-y","volume":"45","author":"LB Li","year":"2024","unstructured":"Li LB, Yang LX, Liu L, Liu FR, Li AH, Zhu YL, Wen H, Xue X, Tian ZX, Sun H, Li PC, Zhao XG. Targeted inhibition of the HNF1A\/SHH axis by triptolide overcomes paclitaxel resistance in non-small cell lung cancer. Acta Pharmacol Sin. 2024a;45:1060\u201376.","journal-title":"Acta Pharmacol Sin"},{"key":"3307_CR62","doi-asserted-by":"publisher","first-page":"117581","DOI":"10.1016\/j.biopha.2024.117581","volume":"180","author":"M Li","year":"2024","unstructured":"Li M, Li J, Tang Q, Zhu Y. Potential antitumor activity of triptolide and its derivatives: Focused on gynecological and breast cancers. Biomed Pharmacother. 2024b;180:117581.","journal-title":"Biomed Pharmacother"},{"key":"3307_CR63","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.3109\/10717544.2015.1028603","volume":"23","author":"X Li","year":"2016","unstructured":"Li X, Mao Y, Li K, Shi T, Yao H, Yao J, Wang S. Pharmacokinetics and tissue distribution study in mice of triptolide-loaded lipid emulsion and accumulation effect on pancreas. Drug Deliv. 2016;23:1344\u201354.","journal-title":"Drug Deliv"},{"key":"3307_CR64","doi-asserted-by":"publisher","first-page":"29740","DOI":"10.1038\/s41598-024-80856-7","volume":"14","author":"X Li","year":"2024","unstructured":"Li X, Shan Y, Wang S, Wang J, Heng X. Triptolide induces apoptosis of glioma cells by inhibiting NF-\u03baB activation during oxidative stress. Sci Rep. 2024c;14:29740.","journal-title":"Sci Rep"},{"key":"3307_CR65","doi-asserted-by":"publisher","first-page":"17108","DOI":"10.1021\/acsomega.4c04743","volume":"10","author":"X Li","year":"2025","unstructured":"Li X, Su Y, Lin N, Chen Y, Li Z, Zhang Z, Zhao X, Zeng H. Lycium barbarum Polysaccharide-Stabilized Selenium Nanoparticles Deliver Triptolide to Induce Apoptosis for Pancreatic Cancer In Vitro and In Vivo. ACS Omega. 2025;10:17108\u201322.","journal-title":"ACS Omega"},{"key":"3307_CR66","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1186\/s12951-021-01095-w","volume":"19","author":"Z Li","year":"2021","unstructured":"Li Z, Yang G, Han L, Wang R, Gong C, Yuan Y. Sorafenib and triptolide loaded cancer cell-platelet hybrid membrane-camouflaged liquid crystalline lipid nanoparticles for the treatment of hepatocellular carcinoma. J Nanobiotechnol. 2021a;19:360.","journal-title":"J Nanobiotechnol"},{"key":"3307_CR67","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1186\/s12951-021-01095-w","volume":"19","author":"Z Li","year":"2021","unstructured":"Li Z, Yang G, Han L, Wang R, Gong C, Yuan Y. Sorafenib and triptolide loaded cancer cell-platelet hybrid membrane-camouflaged liquid crystalline lipid nanoparticles for the treatment of hepatocellular carcinoma. J Nanobiotechnol. 2021b;19:360.","journal-title":"J Nanobiotechnol"},{"key":"3307_CR68","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1016\/j.jconrel.2020.12.003","volume":"329","author":"K Liaw","year":"2021","unstructured":"Liaw K, Sharma R, Sharma A, Salazar S, Appiani La Rosa S, Kannan RM. Systemic dendrimer delivery of triptolide to tumor-associated macrophages improves anti-tumor efficacy and reduces systemic toxicity in glioblastoma. J Control Release. 2021;329:434\u201344.","journal-title":"J Control Release"},{"key":"3307_CR69","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1093\/annonc\/mdp315","volume":"21","author":"WT Lim","year":"2010","unstructured":"Lim WT, Tan EH, Toh CK, Hee SW, Leong SS, Ang PCS, Wong NS, Chowbay B. Phase I pharmacokinetic study of a weekly liposomal paclitaxel formulation (Genexol-PM) in patients with solid tumors. Ann Oncol. 2010;21:382\u20138.","journal-title":"Ann Oncol"},{"key":"3307_CR70","doi-asserted-by":"publisher","first-page":"8027","DOI":"10.1021\/nn502074x","volume":"8","author":"D Ling","year":"2014","unstructured":"Ling D, Xia H, Park W, Hackett MJ, Song C, Na K, Hui KM, Hyeon T. pH-sensitive nanoformulated triptolide as a targeted therapeutic strategy for hepatocellular carcinoma. ACS Nano. 2014;8:8027\u201339.","journal-title":"ACS Nano"},{"key":"3307_CR71","first-page":"830","volume":"16","author":"H Liu","year":"2018","unstructured":"Liu H, Tang L, Li X, Li H. Triptolide inhibits vascular endothelial growth factor-mediated angiogenesis in human breast cancer cells. Exp Ther Med. 2018a;16:830\u20136.","journal-title":"Exp Ther Med"},{"key":"3307_CR72","doi-asserted-by":"crossref","unstructured":"Liu J, Cheng H, Han L, Qiang Z, Zhang X, Gao W, Zhao K, Song Y. (2018b) Synergistic combination therapy of lung cancer using paclitaxel- and triptolide-coloaded lipid\u2013polymer hybrid nanoparticles. Drug Design, Development and Therapy 12: 3199\u20133209.","DOI":"10.2147\/DDDT.S172199"},{"key":"3307_CR73","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.1166\/jbn.2018.2633","volume":"14","author":"L Liu","year":"2018","unstructured":"Liu L, Xiong X, Shen M, Ru D, Gao P, Zhang X, Huang C, Sun Y, Li H, Duan Y. Co-delivery of triptolide and curcumin for ovarian cancer targeting therapy via mPEG-DPPE\/CaP nanoparticle. J Biomed Nanotechnol. 2018c;14:1761\u201372.","journal-title":"J Biomed Nanotechnol"},{"key":"3307_CR74","doi-asserted-by":"crossref","unstructured":"Liu Y, Kong L, Yu Y, Zang J, Zhang L, Guo R-B, Li S-T, Cheng L, Li X-T, Chen Y-Q. (2025) Tumor microenvironment responsive key nanomicelles for effective against invasion and metastasis in ovarian cancer using mice model. Int J Nanomed: 215\u201338.","DOI":"10.2147\/IJN.S470219"},{"key":"3307_CR75","doi-asserted-by":"publisher","first-page":"217536","DOI":"10.1016\/j.canlet.2025.217536","volume":"614","author":"S Lorenzoni","year":"2025","unstructured":"Lorenzoni S, Rodriguez-Nogales C, Blanco-Prieto MJ. Targeting tumor microenvironment with RGD-functionalized nanoparticles for precision cancer therapy. Cancer Lett. 2025;614:217536.","journal-title":"Cancer Lett"},{"key":"3307_CR76","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1039\/D4RA06954D","volume":"15","author":"JX Lu","year":"2025","unstructured":"Lu JX, Lan HR, Zeng D, Song JY, Hao YT, Xing AP, Shen A, Yuan J. Design, synthesis, anticancer activity and molecular docking of quinoline-based dihydrazone derivatives. RSC Adv. 2025;15:231\u201343.","journal-title":"RSC Adv"},{"key":"3307_CR77","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/S0168-3659(99)00248-5","volume":"65","author":"H Maeda","year":"2000","unstructured":"Maeda H, Wu J, Sawa T, Matsumura Y, Hori K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release. 2000;65:271\u201384.","journal-title":"J Control Release"},{"key":"3307_CR78","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1186\/s13046-025-03391-x","volume":"44","author":"MTD Martino","year":"2025","unstructured":"Martino MTD, Tagliaferri P, Tassone P. MicroRNA in cancer therapy: breakthroughs and challenges in early clinical applications. J Experimental Clin Cancer Res. 2025;44:126.","journal-title":"J Experimental Clin Cancer Res"},{"key":"3307_CR79","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1081\/DDC-200047791","volume":"31","author":"Z Mei","year":"2005","unstructured":"Mei Z, Wu Q, Hu S, Li X, Yang X. Triptolide loaded solid lipid nanoparticle hydrogel for topical application. Drug Dev Ind Pharm. 2005;31:161\u20138.","journal-title":"Drug Dev Ind Pharm"},{"key":"3307_CR80","first-page":"622","volume":"26","author":"C Meng","year":"2014","unstructured":"Meng C, Zhu H, Song H, Wang Z, Huang G, Li D, Ma Z, Ma J, Qin Q, Sun X, Ma J. Targets and molecular mechanisms of triptolide in cancer therapy. Chin J Cancer Res. 2014;26:622\u20136.","journal-title":"Chin J Cancer Res"},{"key":"3307_CR81","doi-asserted-by":"crossref","unstructured":"Mitchell MJ, Billingsley MM, Haley RM, Wechsler ME, Peppas NA. Langer RJNrdd (2021) Engineering precision nanoparticles for drug delivery. 20: 101\u2013124.","DOI":"10.1038\/s41573-020-0090-8"},{"key":"3307_CR82","doi-asserted-by":"publisher","first-page":"8367","DOI":"10.3390\/molecules27238367","volume":"27","author":"A Naeem","year":"2022","unstructured":"Naeem A, Hu P, Yang M, Zhang J, Liu Y, Zhu W, Zheng Q. Natural products as anticancer agents: current status and future perspectives. Molecules. 2022;27:8367.","journal-title":"Molecules"},{"key":"3307_CR83","doi-asserted-by":"crossref","unstructured":"Niculescu AG, Grumezescu AM. (2022) Novel Tumor-Targeting Nanoparticles for Cancer Treatment-A Review. Int J Mol Sci 23.","DOI":"10.3390\/ijms23095253"},{"key":"3307_CR84","doi-asserted-by":"publisher","first-page":"9334","DOI":"10.1021\/acs.jmedchem.5b01329","volume":"58","author":"S Patil","year":"2015","unstructured":"Patil S, Lis LG, Schumacher RJ, Norris BJ, Morgan ML, Cuellar RA, Blazar BR, Suryanarayanan R, Gurvich VJ, Georg GI. Phosphonooxymethyl Prodrug of Triptolide: Synthesis, Physicochemical Characterization, and Efficacy in Human Colon Adenocarcinoma and Ovarian Cancer Xenografts. J Med Chem. 2015;58:9334\u201344.","journal-title":"J Med Chem"},{"key":"3307_CR85","doi-asserted-by":"crossref","unstructured":"Qi Y, Yu Z, Zhang J, Zhang C, Wang X, Yang F, Bai Y, Yuan J-X, Guo M, Wang D, Hu K, Zhou T, Wang L, Rao W. (2026) Liquid Metal Nanoparticles-Mediated Mitochondrial Damage Enhances Immunogenic Cell Death for Cancer Vaccine Therapy. Advanced Materials n\/a: e20580.","DOI":"10.1002\/adma.202520580"},{"key":"3307_CR86","first-page":"3929","volume":"16","author":"G Qin","year":"2018","unstructured":"Qin G, Li P, Xue Z. Triptolide induces protective autophagy and apoptosis in human cervical cancer cells by downregulating Akt\/mTOR activation. Oncol Lett. 2018;16:3929\u201334.","journal-title":"Oncol Lett"},{"key":"3307_CR87","doi-asserted-by":"publisher","first-page":"1","DOI":"10.71193\/jpci.20250005","volume":"1","author":"IH Rakib","year":"2025","unstructured":"Rakib IH, Hossan R, Al Hasan MS, Yana NT, Safa FA, Sumaya UH. Anticancer Activity of Scutellarein Against Several Cancer Types with Possible Mechanisms: A Mini Review. J Phytochemical Insights. 2025;1:1\u20136.","journal-title":"J Phytochemical Insights"},{"key":"3307_CR88","doi-asserted-by":"crossref","unstructured":"Rao Q, Wang L, Tacke F, Guillot A, Ma N. (2025) Engineering liver disease models in vitro: emerging trends and innovations. eGastroenterology 3.","DOI":"10.1136\/egastro-2025-100279"},{"key":"3307_CR89","first-page":"10","volume":"2","author":"MG Rasul","year":"2018","unstructured":"Rasul MG. Conventional extraction methods use in medicinal plants, their advantages and disadvantages. Int J Basic Sci Appl Comput. 2018;2:10\u20134.","journal-title":"Int J Basic Sci Appl Comput"},{"key":"3307_CR90","doi-asserted-by":"crossref","unstructured":"Rodriguez-Blanco J, Salvador AD, Suter RK, Swiderska-Syn M, Palomo-Caturla I, Kliebe V, Shahani P, Peterson K, Turos-Cabal M, Vieira ME, Wynn DT, Howell AJ, Yang F, Ban Y, McCrea HJ, Zindy F, Danis E, Vibhakar R, Jermakowicz A, Martin V, Coss CC, Harris BT, de Cubas A, Chen XS, Barnoud T, Roussel MF, Ayad NG, Robbins DJ. (2024) Triptolide and its prodrug Minnelide target high-risk MYC-amplified medulloblastoma in preclinical models. J Clin Invest 134.","DOI":"10.1172\/JCI171136"},{"key":"3307_CR91","doi-asserted-by":"publisher","first-page":"102053","DOI":"10.1016\/j.mtbio.2025.102053","volume":"33","author":"AR Sampaio","year":"2025","unstructured":"Sampaio AR, Maia RF, Ciardulli MC, Santos HA, Sarmento B. Organ-on-chip platforms for nanoparticle toxicity and efficacy assessment: Advancing beyond traditional in vitro and in vivo models. Mater Today Bio. 2025;33:102053.","journal-title":"Mater Today Bio"},{"key":"3307_CR92","doi-asserted-by":"publisher","first-page":"978","DOI":"10.22214\/ijraset.2025.66446","volume":"13","author":"A Sayyad","year":"2025","unstructured":"Sayyad A. Nanotechnology in Cancer Therapy: A Paradigm Shift in Oncology. Int J Res Appl Sci Eng Technol. 2025;13:978\u201382.","journal-title":"Int J Res Appl Sci Eng Technol"},{"key":"3307_CR93","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.1007\/s10637-021-01137-y","volume":"39","author":"EJ Seo","year":"2021","unstructured":"Seo EJ, Dawood M, Hult AK, Olsson ML, Efferth T. Network pharmacology of triptolide in cancer cells: implications for transcription factor binding. Invest New Drugs. 2021;39:1523\u201337.","journal-title":"Invest New Drugs"},{"key":"3307_CR94","doi-asserted-by":"publisher","first-page":"286","DOI":"10.3389\/fphar.2015.00286","volume":"6","author":"L Sercombe","year":"2015","unstructured":"Sercombe L, Veerati T, Moheimani F, Wu SY, Sood AK, Hua S. Advances and Challenges of Liposome Assisted Drug Delivery. Front Pharmacol. 2015;6:286.","journal-title":"Front Pharmacol"},{"key":"3307_CR95","doi-asserted-by":"crossref","unstructured":"Shah MA, Hamid A, Faheem HI, Rasul A, Baokbah TAS, Haris M, Yousaf R, Saleem U, Iqbal S, Alves MS, Khan Z, Hussain G, Alsharfi I, Khan H, Jeandet P. (2022) Uncovering the Anticancer Potential of Polydatin: A Mechanistic Insight. Molecules 27.","DOI":"10.3390\/molecules27217175"},{"key":"3307_CR96","doi-asserted-by":"publisher","first-page":"8","DOI":"10.4103\/ajio.ajio_3_25","volume":"2","author":"S Sharma","year":"2025","unstructured":"Sharma S, Kumar C, Kushwaha H, Sahil, Jha SK, Chawla S, Sharma A, Midha T, Huddar V. Advancing anticancer drug development: Overcoming challenges and exploring new therapeutic strategies. Ayush J Integr Oncol. 2025;2:8\u201327.","journal-title":"Ayush J Integr Oncol"},{"key":"3307_CR97","doi-asserted-by":"crossref","unstructured":"Sharmila A, Bhadra P, Kishore C, Selvaraj CI, Kavalakatt J, Bishayee A. (2025a) Nanoformulated Terpenoids in Cancer: A Review of Therapeutic Applications, Mechanisms, and Challenges. Cancers (Basel) 17.","DOI":"10.3390\/cancers17183013"},{"key":"3307_CR98","doi-asserted-by":"publisher","first-page":"3013","DOI":"10.3390\/cancers17183013","volume":"17","author":"A Sharmila","year":"2025","unstructured":"Sharmila A, Bhadra P, Kishore C, Selvaraj CI, Kavalakatt J, Bishayee A. Nanoformulated Terpenoids in Cancer: A Review of Therapeutic Applications, Mechanisms, and Challenges. Cancers. 2025b;17:3013.","journal-title":"Cancers"},{"key":"3307_CR99","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1186\/s12951-021-00934-0","volume":"19","author":"J Shi","year":"2021","unstructured":"Shi J, Ren Y, Ma J, Luo X, Li J, Wu Y, Gu H, Fu C, Cao Z, Zhang J. Novel CD44-targeting and pH\/redox-dual-stimuli-responsive core\u2013shell nanoparticles loading triptolide combats breast cancer growth and lung metastasis. J Nanobiotechnol. 2021;19:188.","journal-title":"J Nanobiotechnol"},{"key":"3307_CR100","doi-asserted-by":"publisher","first-page":"114705","DOI":"10.1016\/j.biopha.2023.114705","volume":"162","author":"J Song","year":"2023","unstructured":"Song J, He G-N, Dai L. A comprehensive review on celastrol, triptolide and triptonide: Insights on their pharmacological activity, toxicity, combination therapy, new dosage form and novel drug delivery routes. Biomed Pharmacother. 2023a;162:114705.","journal-title":"Biomed Pharmacother"},{"key":"3307_CR101","doi-asserted-by":"publisher","first-page":"114705","DOI":"10.1016\/j.biopha.2023.114705","volume":"162","author":"J Song","year":"2023","unstructured":"Song J, He GN, Dai L. A comprehensive review on celastrol, triptolide and triptonide: Insights on their pharmacological activity, toxicity, combination therapy, new dosage form and novel drug delivery routes. Biomed Pharmacother. 2023b;162:114705.","journal-title":"Biomed Pharmacother"},{"key":"3307_CR102","doi-asserted-by":"publisher","first-page":"943","DOI":"10.3390\/ph18070943","volume":"18","author":"E S\u00f6nmez G\u00fcrer","year":"2025","unstructured":"S\u00f6nmez G\u00fcrer E, Tun\u00e7bilek Z, Zontul C, Kutlay A, Kumar A, Jhaa G. Evaluation and DFT Analysis of In Vitro Anticancer Activity of Consolida orientalis, Smyrnium rotundifolium, and Euphorbia virgata Plant Extracts in Colorectal Cancer. Pharmaceuticals. 2025;18:943.","journal-title":"Pharmaceuticals"},{"key":"3307_CR103","doi-asserted-by":"crossref","unstructured":"Thalij KM, You HW, Aher KB, Bhavar GB, Kumbhar ST, Habeeb MJIJN. (2025) Advances in lipid-based nanomedicine: pathway specific siRNA therapy and optimizing delivery for hepatocellular carcinoma. 10541\u201366.","DOI":"10.2147\/IJN.S532246"},{"key":"3307_CR104","first-page":"1204","volume":"12","author":"L Tian","year":"2019","unstructured":"Tian L, Zhang Y, Wang Y, Dang R, Fu Z, Gu B, Wen N. Triptolide reduces proliferation and enhances apoptosis in drug-resistant human oral cancer cells. Int J Clin Exp Pathol. 2019;12:1204.","journal-title":"Int J Clin Exp Pathol"},{"key":"3307_CR105","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1039\/D0NP00054J","volume":"38","author":"L Tong","year":"2021","unstructured":"Tong L, Zhao Q, Datan E, Lin G-Q, Minn I, Pomper MG, Yu B, Romo D, He Q-L, Liu JO. Triptolide: reflections on two decades of research and prospects for the future. Nat Prod Rep. 2021;38:843\u201360.","journal-title":"Nat Prod Rep"},{"key":"3307_CR106","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1007\/s12672-025-01881-0","volume":"16","author":"S-n Tu","year":"2025","unstructured":"Tu S-n, Hu F, Zhang J, Cai H, Yang J. Research progress on the signaling pathway mechanism of terpenoids against breast cancer. Discover Oncol. 2025;16:433.","journal-title":"Discover Oncol"},{"key":"3307_CR107","doi-asserted-by":"publisher","first-page":"1584","DOI":"10.1007\/s13346-020-00827-z","volume":"10","author":"JSR Viegas","year":"2020","unstructured":"Viegas JSR, Praca FG, Kravicz M, Bentley MVLB. Therapeutic applications and delivery systems for triptolide. Drug Delivery Translational Res. 2020;10:1584\u2013600.","journal-title":"Drug Delivery Translational Res"},{"key":"3307_CR108","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1093\/toxsci\/kfx144","volume":"159","author":"ADB Vliegenthart","year":"2017","unstructured":"Vliegenthart ADB, Wei C, Buckley C, Berends C, de Potter CMJ, Schneemann S, Del Pozo J, Tucker C, Mullins JJ, Webb DJ, Dear JW. Characterization of Triptolide-Induced Hepatotoxicity by Imaging and Transcriptomics in a Novel Zebrafish Model. Toxicol Sci. 2017;159:380\u201391.","journal-title":"Toxicol Sci"},{"key":"3307_CR109","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1166\/jbn.2015.2016","volume":"11","author":"C Wang","year":"2015","unstructured":"Wang C, Shan Y, Yang J, Xu X, Zhuang B, Fan Y, Xu W. Inhibition of Cancer Angiogenesis Using Triptolide Nanoparticles. J Biomed Nanotechnol. 2015;11:805\u201315.","journal-title":"J Biomed Nanotechnol"},{"key":"3307_CR110","doi-asserted-by":"crossref","unstructured":"Wang J, Cui J, Chen Y, Zhou H, Li X, Wu X, Zhou R, Zeng H. (2025) Self-assembled triptolide prodrug nanovesicles loading with ginsenoside Rg3 for double-targeted therapy of pancreatic cancer. Mater Today Bio: 102004.","DOI":"10.1016\/j.mtbio.2025.102004"},{"key":"3307_CR111","doi-asserted-by":"crossref","unstructured":"Wang X, Zeng H, Zhu X, Xu D, Tian Q, Wang C, Zhao L, Zhao J, Miao M, Wu X. (2022) TP-CSO: A Triptolide Prodrug for Pancreatic Cancer Treatment. Molecules 27.","DOI":"10.3390\/molecules27123686"},{"key":"3307_CR112","doi-asserted-by":"crossref","unstructured":"Watkins R, Wu L, Zhang C, Davis RM, Xu B. (2015) Natural product-based nanomedicine: recent advances and issues. Int J Nanomed: 6055\u201374.","DOI":"10.2147\/IJN.S92162"},{"key":"3307_CR113","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.2147\/IJN.S131235","volume":"12","author":"B Wu","year":"2017","unstructured":"Wu B, Lu S-T, Zhang L-J, Zhuo R-X, Xu H-B, Huang S-W. Codelivery of doxorubicin and triptolide with reduction-sensitive lipid\u2013polymer hybrid nanoparticles for in vitro and in vivo synergistic cancer treatment. Int J Nanomed. 2017;12:1853\u201362.","journal-title":"Int J Nanomed"},{"key":"3307_CR114","doi-asserted-by":"crossref","unstructured":"Wu Y, Yang Y, Lv X, Gao M, Gong X, Yao Q, Liu Y. (2023) Nanoparticle-based combination therapy for ovarian cancer. Int J Nanomed: 1965\u201387.","DOI":"10.2147\/IJN.S394383"},{"key":"3307_CR115","first-page":"944","volume":"61","author":"L Xiaofang","year":"2025","unstructured":"Xiaofang L, Na L, Xi R, Huahui Z. Synthesis of triptolide nanoparticles and evaluation of their antitumor activity against pancreatic cancer. J Beijing Normal Univ (Natural Science). 2025;61:944\u201351.","journal-title":"J Beijing Normal Univ (Natural Science)"},{"key":"3307_CR116","doi-asserted-by":"publisher","first-page":"2323","DOI":"10.2147\/IJN.S287732","volume":"16","author":"A Yalikong","year":"2021","unstructured":"Yalikong A, Li X-Q, Zhou P-H, Qi Z-P, Li B, Cai S-L, Zhong Y-S. A Triptolide Loaded HER2-Targeted Nano-Drug Delivery System Significantly Suppressed the Proliferation of HER2-Positive and BRAF Mutant Colon Cancer. Int J Nanomed. 2021;16:2323\u201335.","journal-title":"Int J Nanomed"},{"key":"3307_CR117","doi-asserted-by":"publisher","first-page":"1592066","DOI":"10.3389\/fphar.2025.1592066","volume":"16","author":"T Yan","year":"2025","unstructured":"Yan T, Wang Y, Hou Z, Song P, Wang P, Li J, Zheng J, Lv D. A comprehensive overview of triptolide utilizing nanotechnology and its potential applications in prostate diseases. Front Pharmacol. 2025a;16:1592066.","journal-title":"Front Pharmacol"},{"key":"3307_CR118","doi-asserted-by":"publisher","first-page":"1592066","DOI":"10.3389\/fphar.2025.1592066","volume":"16","author":"T Yan","year":"2025","unstructured":"Yan T, Wang Y, Hou Z, Song P, Wang P, Li J, Zheng J, Lv D. A comprehensive overview of triptolide utilizing nanotechnology and its potential applications in prostate diseases. Front Pharmacol. 2025b;16:1592066.","journal-title":"Front Pharmacol"},{"key":"3307_CR119","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s13020-025-01071-8","volume":"20","author":"J Yang","year":"2025","unstructured":"Yang J, Jiang Y, Li M, Wu K, Wei S, Zhao Y, Shen J, Du F, Chen Y, Deng S. Organoid, organ-on-a-chip and traditional Chinese medicine. Chin Med. 2025;20:22.","journal-title":"Chin Med"},{"key":"3307_CR120","doi-asserted-by":"crossref","unstructured":"Yang Y, Lundqvist A. Immunomodulatory Effects of IL-2 and IL-15; Implications for Cancer Immunotherapy. Cancers (Basel; 2020. p. 12.","DOI":"10.3390\/cancers12123586"},{"key":"3307_CR121","doi-asserted-by":"publisher","first-page":"2004","DOI":"10.1016\/j.apsb.2021.02.001","volume":"11","author":"L Yu","year":"2021","unstructured":"Yu L, Wang Z, Mo Z, Zou B, Yang Y, Sun R, Ma W, Yu M, Zhang S, Yu Z. Synergetic delivery of triptolide and Ce6 with light-activatable liposomes for efficient hepatocellular carcinoma therapy. Acta Pharm Sinica B. 2021;11:2004\u201315.","journal-title":"Acta Pharm Sinica B"},{"key":"3307_CR122","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.1039\/D3MH00092C","volume":"10","author":"Z Yu","year":"2023","unstructured":"Yu Z, Wang D, Qi Y, Liu J, Zhou T, Rao W, Hu K. Autologous-cancer-cryoablation-mediated nanovaccine augments systematic immunotherapy. Mater Horiz. 2023;10:1661\u201377.","journal-title":"Mater Horiz"},{"key":"3307_CR123","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.3389\/fphar.2019.01469","volume":"10","author":"K Yuan","year":"2019","unstructured":"Yuan K, Li X, Lu Q, Zhu Q, Jiang H, Wang T, Huang G, Xu A. Application and Mechanisms of Triptolide in the Treatment of Inflammatory Diseases-A Review. Front Pharmacol. 2019;10:1469.","journal-title":"Front Pharmacol"},{"key":"3307_CR124","first-page":"1049","volume":"9","author":"C Zhang","year":"2014","unstructured":"Zhang C, Peng F, Liu W, Wan J, Wan C, Xu H, Lam CW, Yang X. Nanostructured lipid carriers as a novel oral delivery system for triptolide: induced changes in pharmacokinetics profile associated with reduced toxicity in male rats. Int J Nanomed. 2014;9:1049\u201363.","journal-title":"Int J Nanomed"},{"key":"3307_CR125","doi-asserted-by":"crossref","unstructured":"Zhang L, Yan M, Chen K, Tian Q, Song J, Zhang Z, Xie Z, Yuan Y, Jia Y, Zhu X, Zhang Z, Wu X, Zeng H. (2020) Novel Carboxylated Chitosan-Based Triptolide Conjugate for the Treatment of Rheumatoid Arthritis. Pharmaceutics 12.","DOI":"10.3390\/pharmaceutics12030202"},{"key":"3307_CR126","doi-asserted-by":"crossref","unstructured":"Zhang X, Chen X, Song W, Peng Z. (2025) Pro-drug approaches to overcome poor solubility and toxicity of triptolide. Phytochemistry Reviews.","DOI":"10.1007\/s11101-025-10172-z"},{"key":"3307_CR127","doi-asserted-by":"publisher","first-page":"118721","DOI":"10.1016\/j.ijpharm.2019.118721","volume":"572","author":"W Zheng","year":"2019","unstructured":"Zheng W, Wang C, Ding R, Huang Y, Li Y, Lu Y. Triptolide-loaded nanoparticles targeting breast cancer in vivo with reduced toxicity. Int J Pharm. 2019;572:118721.","journal-title":"Int J Pharm"},{"key":"3307_CR128","doi-asserted-by":"publisher","first-page":"12975","DOI":"10.2147\/IJN.S498099","volume":"19","author":"L Zhou","year":"2024","unstructured":"Zhou L, Du Y, Shang Y, Xiang D, Xia X. A Novel Triptolide Nano-Liposome with Mitochondrial Targeting for Treatment of Hepatocellular Carcinoma. Int J Nanomed. 2024a;19:12975\u201398.","journal-title":"Int J Nanomed"},{"key":"3307_CR129","doi-asserted-by":"publisher","unstructured":"Zhou L, Du Y, Shang Y, Xiang D, Xia X. (2024b) A Novel Triptolide Nano-Liposome with Mitochondrial Targeting for Treatment of Hepatocellular Carcinoma. Int J Nanomed: 19(0), 12975\u201398. https:\/\/doi.org\/10.2147\/IJN.S498099","DOI":"10.2147\/IJN.S498099"}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-026-03307-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12032-026-03307-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-026-03307-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T13:53:01Z","timestamp":1782827581000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12032-026-03307-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,23]]},"references-count":129,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,7]]}},"alternative-id":["3307"],"URL":"https:\/\/doi.org\/10.1007\/s12032-026-03307-5","relation":{},"ISSN":["1559-131X"],"issn-type":[{"value":"1559-131X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,23]]},"assertion":[{"value":"1 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"AI models such as Grammarly and QuillBot has been used for the refinement of English Language in this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"AI Utilization"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Not Applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Clinical trials"}},{"value":"Not Applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}],"article-number":"197"}}